Moxeza
Plague, Sinusitis, prophylaxis of Plague + 7 more
Treatment
9 FDA approvals
7 Active Studies for Moxeza
Treatment for
Plague
What is Moxeza
Moxifloxacin
The Generic name of this drug
Treatment Summary
Moxifloxacin is an antibiotic drug developed by Bayer AG. It is used to treat bacterial infections and is sold under the brand name Avelox or Avalox. It is a type of fluoroquinolone antibiotic.
Avelox
is the brand name
Moxeza Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Avelox
Moxifloxacin
1999
86
Approved as Treatment by the FDA
Moxifloxacin, also known as Avelox, is approved by the FDA for 9 uses including Sinusitis and Sinusitis .
Sinusitis
Sinusitis
Skin Infections
Plague
Community Acquired Pneumonia (CAP)
Plague
prophylaxis of Plague
Bronchitis
Communicable Diseases
Effectiveness
How Moxeza Affects Patients
Moxifloxacin is an antibiotic that can treat infections caused by certain bacteria. It works by blocking the enzyme that helps the bacteria replicate and spread, and is effective against both Gram-positive and Gram-negative bacteria. Some of the bacteria it can treat include Corynebacterium species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneumoniae, Streptococcus
How Moxeza works in the body
Moxifloxacin works by interfering with two essential bacterial enzymes, DNA gyrase and topoisomerase IV, which are responsible for replicating and repairing bacterial DNA. It also helps to prevent the bacterial DNA from being divided into new cells.
When to interrupt dosage
The proposed measure of Moxeza is contingent upon the determined condition, including ocular bacterial infections, Sinusitis and Skin Infections. The dosage amount fluctuates according to the method of delivery (e.g. Solution - Intravenous or Injection, solution - Ophthalmic) featured in the table beneath.
Condition
Dosage
Administration
Community Acquired Pneumonia (CAP)
400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic
Postoperative Infections
400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic
prophylaxis of Plague
400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic
Conjunctivitis, Bacterial
400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic
ocular bacterial infections
400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic
Bronchitis
400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic
Postoperative Inflammatory Response
400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic
Communicable Diseases
400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic
Plague
400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic
Sinusitis
400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic
Warnings
There are 20 known major drug interactions with Moxeza.
Common Moxeza Drug Interactions
Drug Name
Risk Level
Description
Amiodarone
Major
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Amiodarone.
Amitriptyline
Major
Moxifloxacin may increase the QTc-prolonging activities of Amitriptyline.
Anagrelide
Major
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Anagrelide.
Arsenic trioxide
Major
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Arsenic trioxide.
Artemether
Major
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Artemether.
Moxeza Toxicity & Overdose Risk
Signs of an overdose on zopiclone may include reduced alertness, sleepiness, shaking, seizures, vomiting, and diarrhea. The minimum amount required to be fatal in mice and rats is 100mg/kg.
Moxeza Novel Uses: Which Conditions Have a Clinical Trial Featuring Moxeza?
24 active trials are currently in progress to investigate the potential of Moxeza to serve as a prophylaxis for Plague, Skin Infections and Bacterial Conjunctivitis.
Condition
Clinical Trials
Trial Phases
Postoperative Inflammatory Response
0 Actively Recruiting
Plague
0 Actively Recruiting
Postoperative Infections
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Conjunctivitis, Bacterial
0 Actively Recruiting
ocular bacterial infections
0 Actively Recruiting
Sinusitis
2 Actively Recruiting
Not Applicable
prophylaxis of Plague
0 Actively Recruiting
Bronchitis
0 Actively Recruiting
Community Acquired Pneumonia (CAP)
5 Actively Recruiting
Not Applicable, Phase 1, Phase 3
Moxeza Reviews: What are patients saying about Moxeza?
5
Patient Review
10/7/2013
Moxeza for Pink Eye from Bacterial Infection
5
Patient Review
3/13/2014
Moxeza for Pink Eye from Bacterial Infection
3.7
Patient Review
1/4/2016
Moxeza for Pink Eye from Bacterial Infection
3.7
Patient Review
3/27/2015
Moxeza for Pink Eye from Bacterial Infection
3.3
Patient Review
5/10/2014
Moxeza for Pink Eye from Bacterial Infection
2.3
Patient Review
4/17/2019
Moxeza for Pink Eye from Bacterial Infection
2
Patient Review
11/28/2013
Moxeza for Pink Eye from Bacterial Infection
2
Patient Review
1/6/2015
Moxeza for Ulcer of the Cornea of the Eye with Bacterial Infection
1.7
Patient Review
5/31/2014
Moxeza for Pink Eye from Bacterial Infection
1.7
Patient Review
8/24/2013
Moxeza for Pink Eye from Bacterial Infection
1.3
Patient Review
1/5/2014
Moxeza for Pink Eye from Bacterial Infection
1.3
Patient Review
9/29/2016
Moxeza for Pink Eye from Bacterial Infection
1.3
Patient Review
7/24/2014
Moxeza for Pink Eye from Bacterial Infection
1.3
Patient Review
5/14/2014
Moxeza for Pink Eye from Bacterial Infection
1
Patient Review
4/17/2019
Moxeza for Pink Eye from Bacterial Infection
1
Patient Review
11/30/2016
Moxeza for Pink Eye from Bacterial Infection
Patient Q&A Section about moxeza
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who makes Moxeza?
"Lupin has introduced a new generic treatment option for bacterial conjunctivitis in the form of a 0.5% moxifloxacin ophthalmic solution. This comes after receiving the Food and Drug Administration's approval earlier."
Answered by AI
Does Moxeza have generic?
"- On this day, Lupin launched a generic version of Alcon's Moxeza solution, rated AT. The solution is approved for treating bacterial conjunctivitis caused by susceptible strains of organisms."
Answered by AI
What is Moxeza used for?
"Moxeza is a eye drop used to treat bacterial conjunctivitis or other bacterial infections of the eyes."
Answered by AI
What is the difference between Vigamox and Moxeza?
"The side effects of Vigamox include blurred vision and different eye reactions than those of Moxeza, such as pain, dryness, redness, itching, burning, and stinging. Moxeza may also cause inflammation of the eye, while Vigamox may interact with other eye medications."
Answered by AI